Trilaciclib Granted Fast Track Designation by the U.S. FDA for Use in Combination with Chemotherapy for the Treatment of TNBC

Phase Ⅱ Clinical Data of Envafolimab in MSI-H/dMMR Solid Tumors Published in the Journal of Hematology & Oncolog

Envafolimab Obtained Its 2nd Orphan Drug Designation from the U.S. Food and Drug Administration

Simcere and Vivoryon Therapeutics Announce Strategic Regional Licensing Partnership for N3pE Amyloid-Targeting Medicines to Treat Alzheimer’s Disease in Greater China

Iremod ^® (Iguratimod Tablets) Press Conference on Phase IV Clinical Study Results Held in Beijing

Simcere Announces the Approval of Clinical Trial Application by NMPA to Initiate China Phase Ⅲ Study Sites for the Global Clinical Trial of Trilaciclib in the Treatment of Triple-Negative Breast Cancer (TNBC)

IND Application of Envafolimab in Combination with Lenvatinib in the Treatment of Advanced Solid Tumors has been Approved

Simcere Unveils Latest Clinical Data of Iguratimod and Abatacept at EULAR

Simcere Published its First Environmental, Social and Governance (ESG) Report

Simcere Will Announce Progress of Multiple Clinical Research on Antitumor Drugs at the 2021 ASCO Annual Meeting